Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb everolimus-eluting fully bioresorbable vascular scaffold: Optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients with de Novo Native Coronary Artery Lesions)

JACC: Cardiovascular Interventions

Volumn 7, Issue 12, 2014, Pages 1400-1411

  Onuma, Yoshinobu ^a   Serruys, Patrick W ^a   Muramatsu, Takashi ^a   Nakatani, Shimpei ^a   Van Geuns, Robert Jan ^a   De Bruyne, Bernard ^b   Dudek, Dariusz ^c   Christiansen, Evald ^d   Smits, Pieter C ^e   Chevalier, Bernard ^f   McClean, Dougal ^g   Koolen, Jacques ^h   Windecker, Stephan ⁱ   Whitbourn, Robert ^j   Meredith, Ian ^k   Garcia Garcia, Hector M ^l   Veldhof, Susan ^m   Rapoza, Richard ^m   Ormiston, John A ⁿ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIOVASCULAR CENTER   (Belgium)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e Maasstad Hospital ^*  (Netherlands)

^f INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^g CHRISTCHURCH HOSPITAL   (New Zealand)

^h CATHARINA HOSPITAL   (Netherlands)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j ST VINCENT S HOSPITAL   (Australia)

^k MONASH UNIVERSITY   (Australia)

^l CARDIALYSIS   (Netherlands)

^m ABBOTT VASCULAR   (United States)

ⁿ AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

Atherosclerosis; Biodegradable polymer; Bioresorbable scaffold; Everolimus; Stent

Indexed keywords

CONTRAST MEDIUM; TROPONIN; CARDIOVASCULAR AGENT; EVEROLIMUS; RAPAMYCIN;

ACUTE DISEASE; ACUTE SCAFFOLD DISRUPTION; AGED; ANGIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; CONTRAST ENHANCEMENT; CORONARY ARTERY OBSTRUCTION; CORONARY STENTING; DEVICE SAFETY; DRUG ELUTING CORONARY STENT; EVEROLIMUS ELUTING CORONARY STENT; FOLLOW UP; HUMAN; INCIDENCE; LATE STRUT DISCONTINUITY; MAJOR CLINICAL STUDY; MALE; METAL STENT; MULTICENTER STUDY (TOPIC); OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPEAT PROCEDURE; STABLE ANGINA PECTORIS; STENT COMPLICATION; STENT MALAPPOSITION; VERY ELDERLY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DEVICES; DRUG ELUTING STENT; FEMALE; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROSTHESIS DESIGN; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; SIROLIMUS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84922578276     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.06.016     Document Type: Article

References (23)

1. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57: 1314-22.
2. Räber L, Baumgartner S, Garcia HM, et al. Longterm vascular healing in response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography study. J Am Coll Cardiol Intv 2012;5: 946-57.
3. Farooq V, Vergouwe Y, Räber L, et al. Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J 2012; 33:3098-104.
4. Gonzalo N, Serruys PW, Garcia-Garcia HM, et al. Quantitative ex vivo and in vivo comparison of lumen dimensions measured by optical coherence tomography and intravascular ultrasound in human coronary arteries. Rev Esp Cardiol 2009;62: 615-24.
5. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012;33:16-25b.
6. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371: 899-907.
7. Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2010;6:447-53.
8. Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010;122:2301-12.
9. Gomez-Lara J, Brugaletta S, Diletti R, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 2011;32: 294-304.
10. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988;77:361-71.
11. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12:616-23.
12. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 2011; 123:779-97.
13. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv 2011;4:535-8.
14. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-88.
15. Okamura T, Garg S, Gutiérrez-Chico J, et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1. 0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010;5:932-8.
16. Sihan K, Botha C, Post F, et al. Fully automatic three-dimensional quantitative analysis of intracoronary optical coherence tomography: method and validation. Catheter Cardiovasc Interv 2009; 74:1058-65.
17. Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 2010;31:401-15.
18. Gonzalo N, Serruys PW, Okamura T, et al. Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall: a systematic quantitative approach. Heart 2009;95:1913-9.
19. Regar E, van Leeuwen AMGJ, Serruys PW. Optical Coherence Tomography in Cardiovascular Research. London: Informa Healthcare, 2007.
20. Gomez-Lara J, Radu M, Brugaletta S, et al. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. J Am Coll Cardiol Intv 2011;4: 992-1001.
21. Radu MD. The Clinical Atlas of Intravascular Optical Coherence Tomography for iPad. Eur Heart J 2012;33:1174-5.
22. Gomez-Lara J, Diletti R, Brugaletta S, et al. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. EuroIntervention 2012;8: 214-24.
23. Gomez-Lara J, Brugaletta S, Diletti R, et al. Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Catheter Cardiovasc Interv 2012; 79:890-902.